Main content

  1. Quirin Bachmann
  2. Christoph Schmaderer

Date created: | Last Updated:


Creating DOI. Please wait...

Create DOI

Category: Project

Description: The aim of this systematic review is to synthetize evidence for the immune response to additional doses of SARS-CoV-2- vaccines after full immunization and vaccine efficacy. Adverse events, especially concerning de-novo-formation of donor-specific antibodies and acute graft rejections will also be reported. We will include analyses of the vaccines appproved for emergency use by the EMA and also by the WHO. In addition, we will include Sputnik V (Gamaleya Gam-COVID-Vac vaccine) despite pending approval by EMA or WHO because of its wide distribution in 74 countries as of February 14th. - Cominarty (BioNTech and Pfizer), also Tozinameran, BNT162b2 - Nuvaxovid (Novavax), also NVX-CoV2373 and their formulations - Spikevax (Moderna), also mRNA-1273 - Vaxzevria (Oxford/AstraZeneca), also AZD1222, ChAdOx1 nCoV-19 and their formulations - COVID-19 Vaccine Janssen (Johnson & Johnson), also Ad26COVS1, JNJ-78436735 - Sinovac, also Coronavac - Covilo (Sinopharm (Beijing)), also BBIBP-CorV (Vero Cells) - Covaxin (Bharat Biotech), also BBV152


Loading files...


Recent Activity

Loading logs...

OSF does not support the use of Internet Explorer. For optimal performance, please switch to another browser.
This website relies on cookies to help provide a better user experience. By clicking Accept or continuing to use the site, you agree. For more information, see our Privacy Policy and information on cookie use.

Start managing your projects on the OSF today.

Free and easy to use, the Open Science Framework supports the entire research lifecycle: planning, execution, reporting, archiving, and discovery.